# Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

> **NCT03988023** · PHASE3 · TERMINATED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 1043 (actual)

## Conditions studied

- Severe Osteoarthritis of the Knee

## Interventions

- **BIOLOGICAL:** Ampion
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT03988023
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-24
- **Primary completion:** 2021-07-13
- **Final completion:** 2021-07-13
- **Target enrollment:** 1043 (ACTUAL)
- **Why stopped:** The AP-013 study was prematurely terminated by the sponsor after Data Safety Monitoring Board (DSMB) guidance.
- **Last updated:** 2022-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988023, "Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03988023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*